Taibang with the GMP certificate, expects to commence commercial manufacturing of FVIII products, which are used to treat hemophilia A.
The subsidiary is also considering to construct an additional manufacturing facility for FVIII to meet the growing demand for the product in Chinese market.
China Biologic Products chairman and CEO David Gao said China Biologic with the latest development at Taibang now offers the market all three major categories of blood products through the addition of coagulation factor products.
”’To supply FVIII will significantly improve the market penetration of our plasma-based offering and further strengthen our competitive position as one of China’s top plasma-based biopharmaceutical companies," Gao added.